Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia

article

Fecha

2011-09

Registro en:

SOARES, Bruno Lobão et al.Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia. Revista Brasileira de Psiquiatria, v. 33, p. 223-224, 2011. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462011000300003&lng=en&tlng=en>. Acesso em: 23 mar. 2018.

1809-452X

https://repositorio.ufrn.br/jspui/handle/123456789/25437

http://dx.doi.org/10.1590/S1516-44462011000300003

http://repositorioslatinoamericanos.uchile.cl/handle/2250/3961603

Autor

Soares, Bruno Lobão

Oliveira, João Paulo Maia de

Machado-de-Sousa, João Paulo

Baker, Glen B.

Dursun, Serdar

Hallak, Jaime E. C.

Institución

Universidade Federal do Rio Grande do Norte (Brasil)

Materias

Mostrar el registro completo del ítem